Shuraila F Zerp1, Conchita Vens1, Ben Floot1, Marcel Verheij2, Baukelien van Triest3. 1. Division of Biological Stress Response, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 2. Division of Biological Stress Response, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: m.verheij@nki.nl. 3. Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Abstract
BACKGROUND: APO866 is a highly specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), inhibition of which reduces cellular NAD(+) levels. In this study we addressed the potential of NAD(+) depletion as an anti-cancer strategy and assessed the combination with radiation. METHODS: The anticipated radiosensitizing property of APO866 was investigated in prostate cancer cell lines PC3 and LNCaP in vitro and in PC3 xenografts in vivo. RESULTS: We show that APO866 treatment leads to NAD(+) depletion. Combination experiments with radiation lead to a substantial decrease in clonogenic cell survival in PC3 and LNCaP cells. In PC3 xenografts, treatment with APO866 resulted in reduced intratumoral NAD(+) levels and induced significant tumor growth delay. Combined treatment of APO866 and fractionated radiation was more effective than the single modalities. Compared with untreated tumors, APO866 and radiation alone resulted in tumor growth delays of 14 days and 33 days, respectively, whereas the combination showed a significantly increased tumor growth delay of 65 days. CONCLUSIONS: Our studies show that APO866-induced NAD(+) depletion enhances radiation responses in tumor cell survival in prostate cancer. However, the in vitro data do not reveal a solid cellular mechanism to exploit further clinical development at this moment.
BACKGROUND:APO866 is a highly specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), inhibition of which reduces cellular NAD(+) levels. In this study we addressed the potential of NAD(+) depletion as an anti-cancer strategy and assessed the combination with radiation. METHODS: The anticipated radiosensitizing property of APO866 was investigated in prostate cancer cell lines PC3 and LNCaP in vitro and in PC3 xenografts in vivo. RESULTS: We show that APO866 treatment leads to NAD(+) depletion. Combination experiments with radiation lead to a substantial decrease in clonogenic cell survival in PC3 and LNCaP cells. In PC3 xenografts, treatment with APO866 resulted in reduced intratumoral NAD(+) levels and induced significant tumor growth delay. Combined treatment of APO866 and fractionated radiation was more effective than the single modalities. Compared with untreated tumors, APO866 and radiation alone resulted in tumor growth delays of 14 days and 33 days, respectively, whereas the combination showed a significantly increased tumor growth delay of 65 days. CONCLUSIONS: Our studies show that APO866-induced NAD(+) depletion enhances radiation responses in tumor cell survival in prostate cancer. However, the in vitro data do not reveal a solid cellular mechanism to exploit further clinical development at this moment.
Authors: Joshua E Lewis; Naveen Singh; Reetta J Holmila; Baran D Sumer; Noelle S Williams; Cristina M Furdui; Melissa L Kemp; David A Boothman Journal: Semin Radiat Oncol Date: 2019-01 Impact factor: 5.934
Authors: Kayvan R Keshari; David M Wilson; Mark Van Criekinge; Renuka Sriram; Bertram L Koelsch; Zhen J Wang; Henry F VanBrocklin; Donna M Peehl; Tom O'Brien; Deepak Sampath; Richard A D Carano; John Kurhanewicz Journal: Prostate Date: 2015-07-14 Impact factor: 4.104
Authors: Ling Liu; Xiaoyang Su; William J Quinn; Sheng Hui; Kristin Krukenberg; David W Frederick; Philip Redpath; Le Zhan; Karthikeyani Chellappa; Eileen White; Marie Migaud; Timothy J Mitchison; Joseph A Baur; Joshua D Rabinowitz Journal: Cell Metab Date: 2018-05-01 Impact factor: 27.287
Authors: Sarmishtha De; Elise G Holvey-Bates; Kala Mahen; Belinda Willard; George R Stark Journal: Proc Natl Acad Sci U S A Date: 2021-11-23 Impact factor: 11.205
Authors: Elena Sidorova-Darmos; Robert G Wither; Natalya Shulyakova; Carl Fisher; Melanie Ratnam; Michelle Aarts; Lothar Lilge; Philippe P Monnier; James H Eubanks Journal: Front Aging Neurosci Date: 2014-12-18 Impact factor: 5.750